Phase 4 N=105 The Effects of Montelukast on Smokers With Asthma
Asthmatic Smokers · Non-asthmatic Smokers
Primary: Sputum Neutrophil Percentages — 86.00; 72.53; 89.33; 79.84 percentage of neutrophils
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=35 Inhalation of Corticosteroids in Smoking and Non-smoking Asthmatics.
Asthma
Primary: Late Asthmatic Response (LAR) - Smokers: Absolute Change From Saline in Minimum Forced Expiratory Volume in One Second (FEV1) Between 4-10 Hours (Hrs) After Allergen…
N/A N=17 E-cigarettes for Harm Reduction in Adults With Asthma
Smoking · Asthma · Electronic Cigarette Use
Primary: Change in Cigarettes Per Day From Baseline to Week 8 and Week 16 — 16.34; 15.39; 9.51; 8.66 cigarettes per day — p=.004
Phase 3 N=1,019 Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED)
Asthma
Primary: Percentage of Asthma-control Days Over the 6-month Treatment Period — 50.70; 53.30; 43.84 Percentage of days
N/A N=60 Health Effects of Diesel Exhaust in Asthmatic Patients: A Real-world Study in a London Street
Asthma
Primary: Spirometry, Percentage Change in FEV1 From Baseline — -1.0; -4.8; -2.2; -7.4 percentage change in FEV1 from baseline — p=<0.05
N/A N=18 Airway Smooth Muscle and Asthma Severity
Asthma
Primary: Difference in ASM Mass Between Groups
N/A N=31 Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment
Smoking
Primary: Airway Blood Flow — 2.13; 13.05 ΔQaw (ul/min/ml)
N/A N=15 Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers
Tobacco Abuse Smoke
Primary: Albuterol Induced Change in Qaw Before and After Fluticasone or Placebo — 40.9; 0.0 % change
Phase 2 N=49 Oxidative Stress in Asthma
Asthma · Obesity
Primary: Percentage of Neutrophils in Peripheral Blood — 57.3; 55.4 percentage of neutrophils — p=0.53
N/A N=165 NICU Asthma Education and Secondhand Smoke Reduction Study
Respiratory Illness
Primary: Infants Living in Smoke-free Environments. — 65; 64 participants
N/A N=23 Effects of Reducing Indoor Air Pollution on the Adult Asthmatic Response
Asthma
Primary: PM2.5 Concentration (ug/m^3) — 18.95; 32.73 ug/m^3
N/A N=60 Health Effects of Secondhand Smoke Exposure in Outdoor Smoking Areas in Patients With COPD and Asthma ( TackSHSWP5 )
COPD · Asthma · Second Hand Tobacco Smoke
Primary: Respiratory Rate — 21.66; 21.57 BR/M breathing rate per min
N/A N=43 Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
Phase 2 N=18 PEEP as Rescue Therapy for Asthmatics With Elevated BMI
Asthma
Primary: Central and Peripheral Elastance — 391; 461; 587; 334 cmH2O/L
Early Phase 1 N=39 Defining and Treating Depression-related Asthma
Asthma · Depression · Childhood Asthma
Primary: FEV1 Percent Change Post-ipratropium — 10.8 percent change — p=0.032
Phase 4 N=139 Antidepressant Treatment at an Inner City Asthma Clinic
Depression · Asthma
Primary: Asthma Control Questionnaire (ACQ) — 1.15; 1.63; 1.39; 1.23 units on a scale
N/A N=31 Cigarette Smoking in Smokers With and Without Schizophrenia
Tobacco Dependence · Schizophrenia
Primary: End-of-session Carbon Monoxide — 62.7; 43.0 parts per million (ppm)
Phase 2 N=23 Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics
Asthma
Primary: Airway Reactivity — 5.08; 2.37 mg/ml
N/A N=7 Imaging Study of the Lungs During an Allergic Asthma Attack
Asthma · Atopy
Primary: Percentage Change in the Ratio of Mean-normalized Perfusion Within Ventilation Defective Regions Relative to Outside — -17.8 percentage
N/A N=530 School-based Asthma Therapy: Stage 2 Effectiveness Study
Asthma
Primary: Number of Symptom Free Days — 10.7; 11.6 Days
N/A N=187 Effects Among Smokers Who Use and Do Not Use E-Cigarettes
Toxicant Exposure
Primary: Toxicant Exposure — 40; 97 pg/ml
N/A N=33 Study on the Role of Treatment With Vitamin E on Asthmatic Responses in Allergic Asthmatics
Allergic Asthma
Primary: Effect of Natural-source d-α-tocopheryl Acetate on the Baseline and Allergen-induced Levels of F2-isoprostanes in the Bronchoalveolar Lavage Fluid (BAL)
N/A N=58 Symptom Perception
Asthma
Primary: Asthma Control Questionnaire (ACQ) — 1.2; 1.4; 0.8; 1.4 score on a scale
N/A N=18 Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
Copd · Smoking Cessation · Nicotine Dependence
Primary: Number of Participants Who Achieved 24-hour Smoking Abstinence at End-of-treatment — 1; 1; 2 Participants
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
Tobacco Use Disorder
Primary: Cigarettes Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
N/A N=233 Asthma Symptom Management Through Mindfulness Training
Asthma
Primary: Change From Baseline in Asthma Control at 18 Months — 1.27; 1.17 score on a scale
N/A N=21 Positive Airway Pressure for the Treatment of Asthma
Asthma · Sleep Apnea
Primary: Asthma Control Test — 19.3; 19.8; 19.1; 19.6 units on a scale — p=0.8
N/A N=45 Effect of Whole Body Periodic Acceleration on Airway Endothelial Function
Healthy · Smokers · Asthma
Primary: Airway Blood Flow Response to Albuterol — 2.85; -1.43; 17.93; 4.03 μl/min/ml
Phase 4 N=134 Smoking Cessation in Hispanic Construction Workers
Smoking Cessation
Primary: Prolonged Abstinence Rates — 36.00; 30.43 Percentage of participants
N/A N=169 Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes
Chronic Obstructive Pulmonary Disease · Acute Coronary Syndromes
Primary: COPD Diagnosis — 39 participants